[
    {
        "ExclusionCriteria": "* Diagnosis of definite chronic pancreatitis (CP) at enrollment based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP\n* Potential participants with post-endoscopic retrograde cholangiopancreatography (post- ERCP) AP who are hospitalized for \\<48 hours.\n* Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study\n* Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis\n* Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement)\n* Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure\n* Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures\n* Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of DM and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimate glomerular filtration rate (eGFR) \\< 30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\<12 months.\n* Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety\n* Incarceration\n* Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study",
        "NCTId": "NCT05197920"
    },
    {
        "ExclusionCriteria": "To be eligible a person must not:\n\n* Have diabetes already\n* Have a previous history of being treated with insulin or oral diabetes medications.\n* Currently be using systemic immunosuppressive agents (topical and inhaled agents are acceptable)\n* Have any known serious diseases",
        "NCTId": "NCT00097292"
    },
    {
        "ExclusionCriteria": "1. Current or ongoing use of non-insulin pharmaceuticals or medication that affect glycemic control or glucose homeostasis within 7 days prior to screening or any prohibited concomitant medication listed in section 4.8\n2. Untreated hypothyroidism or active Graves' disease\n3. Concurrent treatment with other immunosuppressive agents (including biologics or steroids), other than inhaled or topical glucocorticoids\n4. Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 1 month prior to Day 0 or superficial skin infection within 1 week prior to Day 0\n5. Active acute or chronic infection requiring treatment with intravenous therapy (IV) within a minimum 1 month prior to Day 0\n\n   a. Specific cases should be reviewed by Infectious Disease Committee prior to enrollment\n6. Have active signs or symptoms of acute infection at the time of the baseline visit (V0).\n7. Significant trauma or major surgery within 1 month of signing informed consent.\n8. Considered in imminent need for surgery or with elective surgery scheduled to occur during the study\n9. History of disseminated herpes zoster or disseminated herpes simplex or a recurrent (more than one episode of) localized, dermatomal herpes zoster\n10. Have evidence of prior or current tuberculosis infection as assessed by Purified Protein Derivative (PPD), interferon gamma release assay (IGRA) or by history\n11. Have evidence of current or past HIV or Hepatitis B infection\n12. Have evidence of active Hepatitis C infection\n13. Have current, confirmed COVID-19 infection\n14. Current or history of Deep vein thrombosis (DVT), Pulmonary embolism (PE), or other thromboembolic events or history of inherited coagulopathies\n15. First degree relative with a history of unprovoked venous thromboembolism (i.e. without known underlying cause such as trauma, surgery, immobilization, prolonged travel, pregnancy, hormone use, or plaster cast), which suggests that a participant may be at increased risk of inherited coagulation disorder\n16. Any present malignancies or history of malignancy, other than a successfully treated nonmelanoma skin cancer\n17. History of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease\n18. Known or suspected polymorphism in the Cytochrome P450 2C19 (CYP2C19 gene, resulting in classification as a poor CYP2C19 metabolizer).\n19. Have renal impairment (eGFR\\< 60 mL/min)\n20. Currently on anti-platelet therapies, excluding low dose aspirin\n21. One or more screening laboratory values as stated\n\n    1. Neutrophils \\< 1,500 /\u03bcL\n    2. Lymphocytes \\< 800 /\u03bcL\n    3. Platelets \\< 150,000 / \u03bcL\n    4. Hemoglobin \\< 6.2 mmol/L (10.0 g/dL)\n    5. Potassium \\> 5.5 mmol/L or \\<3.0 mmol/L\n    6. Sodium \\> 150mmol/L or \\< 130mmol/L\n    7. AST or ALT \u2265 2.5 times the upper limit of normal\n    8. Bilirubin \u2265 1.5 times upper limit of normal unless diagnosed with Gilbert's syndrome\n    9. LDL \\>160 mg/dL\n22. Vaccination with a live virus within the last 6 weeks and killed vaccine within 4 weeks (except 2 weeks for flu vaccine and COVID vaccine)\n23. Be currently pregnant or lactating or anticipate becoming pregnant during the study\n24. Male participants able to father children and female participants of childbearing potential who are unwilling or unable to use 2 effective methods (at least 1 highly effective method) of contraception, including abstinence, as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product\n25. Be currently participating in another T1D treatment study\n26. Have hearing loss with progression over the previous 5 years, or sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating, or progressive\n27. Acute coronary syndrome (e.g., myocardial infarction, unstable angina pectoris) and any history of cerebrovascular disease within 24 weeks before screening; Heart failure NYHA (New York Heart Association) III, NYHA IV\n28. ANY of the following conditions at screening:\n\n    a. Screening 12-lead electrocardiogram (ECG) that demonstrates: i. Clinically significant abnormalities requiring treatment (eg, acute myocardial infarction, serious tachy- or brady-arrhythmias) or indicating serious underlying heart disease (eg, cardiomyopathy, Wolff-Parkinson- White syndrome); ii. Confirmed QT corrected using Fridericia's correction factor (QTcF) prolongation (\\>450 milliseconds).\n\n    b. Long QT Syndrome, a family history of Long QT Syndrome, or a history of Torsades de Pointes (TdP).\n29. History of chronic alcohol abuse or intravenous drug abuse or other illicit drug abuse within 2 years prior to screening\n30. Current or past use of tobacco or nicotine containing products more than the equivalent of 5 cigarettes per day\n31. Participant is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the trial\n32. Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk\n33. Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results",
        "NCTId": "NCT05743244"
    },
    {
        "ExclusionCriteria": "1. One or more screening laboratory values as stated:\n\n   1. Leukocytes \\<3,000/\u03bcL\n   2. Neutrophils \\<1,500/\u03bcL\n   3. Lymphocytes \\<800/\u03bcL\n   4. Platelets \\<100,000/\u03bcL\n   5. Hemoglobin \\<6.2 mmol/L (10.0 g/dL)\n   6. Potassium \\>5.5 mmol/L or \\<3.0 mmol/L\n   7. Sodium \\>150 mmol/L or \\<130 mmol/L\n   8. AST or ALT \u2265 2.5 times the upper limits of normal\n   9. Bilirubin \u2265 1.5 times upper limit of normal\n2. History of immune deficiency\n3. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening visit.\n4. Chronic active infection other than localized skin infections.\n5. Have active signs or symptoms of acute infection at the time of randomization.\n6. Have IgG and/or IgM levels below the normal reference ranges.\n7. Positive PPD, interferon gamma release assay (IGRA) or history of previous treatment for TB.\n8. Vaccination with a live virus within 4 weeks prior to initiating study treatment.\n9. A history of confirmed infectious mononucleosis within the 3 months prior to initiating study treatment, as documented by EBV serology (EBV VCA-IgM and VCA-IgG; PCR would be confirmatory).\n10. Laboratory evidence of current or past HIV or Hepatitis B or active Hepatitis C infection.\n11. Be currently pregnant, lactating or anticipate pregnancy within 14 weeks of the last study drug administration (Visit 15).\n12. Chronic use of oral or inhaled steroids or other immunosuppressive agents.\n13. Known and untreated hypothyroidism or active Graves' disease at randomization.\n14. History of malignancy.\n15. Prior treatment with active study agent from a previous clinical trial.\n16. Any laboratory abnormality or condition that, in the opinion of the investigator, would interfere with the study conduct or the safety of the participant.",
        "NCTId": "NCT03929601"
    },
    {
        "ExclusionCriteria": "1. Participant has any autoimmune disease other than T1D with the exception of stable thyroid or celiac disease\n2. Has an active infection and/or fever\n3. Has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).\n4. Has any condition that, in the opinion of the Investigator, would interfere with the study conduct or the safety of the participant.",
        "NCTId": "NCT05757713"
    },
    {
        "ExclusionCriteria": "1. Subject participated in any Closed Loop study in the past.\n2. Subject is unable to tolerate tape adhesive in the area of sensor placement\n3. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, rash, Staphylococcus infection) or area of infusion set placement\n4. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study\n5. Subject is being treated for hyperthyroidism at time of screening\n6. Subject has an abnormality (out of reference range) in thyroid-stimulating hormone (TSH) at time of screening visit. TSH is not required for subjects 2-13 years of age.\n7. Subject has taken any oral, injectable, or IV glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.\n8. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks\n9. Subject is currently abusing illicit drugs or marijuana\n10. Subject is currently abusing prescription drugs\n11. Subject is currently abusing alcohol\n12. Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists, biguanides, DPP-4 inhibitors or sulfonylureas at time of screening\n13. Subject is using hydroxyurea at the time of screening or plans to use it during the study\n14. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator\n15. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening\n16. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation\n17. Subject diagnosed with current moderate to severe eating disorder such as anorexia or bulimia\n18. Subject has been diagnosed with chronic kidney disease requiring dialysis or resulting in chronic anemia\n19. Subjects who are currently being actively treated for cancer.\n20. Subject who is designated as a research staff member for this study",
        "NCTId": "NCT02748018"
    },
    {
        "ExclusionCriteria": "1. Presence of severe, active disease that interferes with dietary intake or requires the use of chronic medication, with the exception of well-controlled hypothyroidism and mild asthma not requiring oral steroids. Presence of any psychiatric disorder that will affect ability to participate in study.\n2. Diabetes other than T1D\n3. Chronic illness known to affect glucose metabolism (e.g. Cushing syndrome, polycystic ovarian disorder, cystic fibrosis) or taking medications that affect glucose metabolism (e.g. steroids, metformin)\n4. Inability to swallow pills\n5. Psychiatric impairment or current use of anti-psychotic medication\n6. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.\n7. Neutropenia (\\< 1,500 neutrophils/\u03bcL)\n8. Leukopenia (\\< 3,000 leukocytes /\u03bcL)\n9. Lymphopenia ( \\< 800 lymphocytes/\u03bcL)\n10. Thrombocytopenia (\\<100,000 platelets/\u03bcL)\n11. Clinically significant anemia or Hemoglobin as defined below:\n\n    In Adults: Hgb \\<12.0g/dL in females and \\<13.0g/dL in males In Children: 12- \\<18: \\<11.4 g/dL in females and \\<12.4 g/dL in males In Children: 6- \\<12: Hgb \\<11.2 g/dL\n12. Impaired renal function (assessed by history and BUN/Creatinine, DFMO is renally excreted)\n13. Allergy to milk or soy (components of Boost\u00ae drink used for mixed meal tolerance testing)\n14. Female participants of child-bearing age with reproductive potential, must not be pregnant and agree to use 2 effective forms of birth control or be abstinent during the study period (see below). Male participants (including men who have had vasectomies) whose partners are pregnant or may be pregnant should use condoms while on study drug, until 2 weeks after discontinuation of drug, while the partner is pregnant.\n15. Active seizure disorder, defined as requiring chronic medication at the time of study or having had a seizure within the past 12 months at the time of screening\n16. Enrollment into another intervention trial.",
        "NCTId": "NCT05594563"
    },
    {
        "ExclusionCriteria": "1. Immunodeficiency or clinically significant chronic lymphopenia: (Leukopenia (\\< 3,000 leukocytes /\u03bcL), neutropenia (\\<1,500 neutrophils/\u03bcL), lymphopenia (\\<800 lymphocytes/\u03bcL), thrombocytopenia (\\<100,000 platelets/\u03bcL).\n2. Hemoglobin less than 13.5 g/dL for adult men and less than 12 g/dL for adult females and less than 11 g/dL for participants under age 18\n3. Active signs or symptoms of acute infection at the time of randomization including SARS-Cov-2.\n4. Uncontrolled autoimmune thyroid disease and/or celiac disease (participants must be well controlled for the previous 6 months).\n5. Evidence of prior or current tuberculosis infection as assessed interferon gamma release assay (QuantiFERON).\n6. Currently pregnant or lactating or anticipate getting pregnant within the study period.\n7. Require use of other immunosuppressive agents including chronic use of systemic steroids.\n8. Evidence of current or past HIV or Hepatitis B or current Hepatitis C infection.\n9. Any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, COPD, sickle cell disease, neurological disease, or blood count abnormalities.\n10. A history of malignancies other than of skin.\n11. Evidence of liver dysfunction with AST or ALT outside of the reference range.\n12. Evidence of renal dysfunction with creatinine outside of the reference range.\n13. Increased bilirubin (total and direct) outside of the normal limit (Participants with documentation of Gilbert's Disease permitted).\n14. Vaccination with a live virus within the last 4 weeks.\n15. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening\n16. Prior treatment with Teplizumab (either in a previous clinical trial or clinically).\n17. Has participated in a clinical trial for diabetes prevention previously and received active study agent within 3 months of randomization.\n18. Known allergy to ATG or any product excipient\n19. Prior treatment with ATG or known allergy to rabbit-derived products or to any product excipient\n20. Prior adverse reactions to heparin.\n21. Any condition that in the investigator's opinion may adversely affect study participation will be reviewed by the Study Chair to ensure consistency and adjudicate whether or not the subject may compromise the study results\n22. Any screening/baseline laboratory result not otherwise stated out of normal reference range and/or medical history that may increase the risk of the subject's participation in this trial.\n23. Previously diagnosed with Stage 3 TID according to ADA criteria (see Appendix 3 for Criteria for diagnosis of diabetes)",
        "NCTId": "NCT04291703"
    },
    {
        "ExclusionCriteria": "45. Unwilling or unable to comply with study visits and other study procedures as required per protocol\n46. Recovered from severe COVID-19 infection (requiring hospitalization) but with persistent long COVID-19 symptoms (i.e., the individual has not recovered for several weeks or months since the start of symptoms that were suggestive of COVID-19, irrespective if the individual was tested or not)",
        "NCTId": "NCT04419779"
    },
    {
        "ExclusionCriteria": "1. Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and by genetic/antibody testing).\n2. History of ongoing infection or antibiotic treatment within the past month;\n3. History of immune-compromise, recurrent infections, steroid intake (inhaled or oral forms) or other immunosuppressant use in the past 6 months.\n4. History of chronic gastrointestinal disease, possible or confirmed celiac disease;\n5. Participation in any research intervention trials within the past 3 months.\n6. History of treatment or use of metformin, a type 2 diabetes medication.",
        "NCTId": "NCT05414409"
    },
    {
        "ExclusionCriteria": "* Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or\n* Inability to comply with the study visit schedule and required assessments.",
        "NCTId": "NCT02734277"
    },
    {
        "ExclusionCriteria": "* Diagnosis of definite chronic pancreatitis (CP) at enrollment (see also study definitions) based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic Resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP\n* Potential participants with post-endoscopic retrograde cholangiopancreatography (ERCP) AP who are hospitalized for \\<48 hours.\n* Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study\n* Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis\n* Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement).\n* Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure.\n* Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures\n* Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of diabetes mellitus and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimated glomerular filtration rate (eGFR) \\< 30 or on dialysis prior to AP, and decompensated cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\<12 months\n* Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety as detailed in the Manual of Procedures\n* Incarceration\n* Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study",
        "NCTId": "NCT06401577"
    }
]